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72 Poster Session-Itransplant for graft failure). Average pre apheresis costs per patient
were $1800 (clinic visit, laboratory evaluation, central venous cathe-
ter insertion, and chest x-ray to check placement). The average costs
of chemotherapy administration, hospitalization, prophylactic anti-
biotics and G-CSF were $29181 (not including rituximab). This
does not include supportive care, I/V fluids, readmission costs or
professional fees. Post apheresis costs were $2493.
Conclusions: Interventions or newer agents that reduce the fail-
ure rate or the number of apheresis procedures required to reach
a target HPC dose without increasing the toxicity may reduce total
transplant costs.The financial implication for transplant centers
where reimbursement is DRG (diagnosis related group) or case
rate based is significant.
Estimated Chemo Mobilization Costs
National Hospital Median Estimated Total
Cost Item Average Cost (USD) (Range) Costs (USD)Daily room charge
for chemo
administration$863 6 (3–28) $5,178Ifosfamide 3.33 g/m2/d
x 3 d$372.87/gram 19.38g $7,227Etoposide 150mg/m2
 6 d$17.61/10mg 1,746mg $3,074Daily CBC, diff $93 5 (3–28) $465
Readmission, daily
room charge
(n524)$863 5 (1–12) $4,315Blood transfusions
(n564)$494 1.4 (0–6) $692Platelet transfusions
(n564)$494 1.5 (0–7) $741Oral antibiotics 9 (0–16) $104
Apheresis procedure $1,917.73 2 (1–7) $3,835
PB CD341 analysis $135 2 (estimated) $270
Total (without rituximab) $36,454Source: Cleverly and Associates; www.drugstore.com; Redbooke;
Thompson PDR.195
SALVAGE AND HEMATOPOIETIC RECOVERY WITH BORTEZOMIB AND
MELPHALAN IN CYTOPENIC RECURRENT AND REFRACTORY MULTIPLE
MYELOMA
Mazumder, A., Vesole, D., Jagannath, S. St. Vincents Cancer Center,
New York, NY
The management of relapsed and refractory multiple myeloma
(RRMM) remains difficult. Patients have short response duration,
become cytopenic and are not eligible for clinical trials of promising
new drugs. They often have inadequate numbers of stem cells (\3
10(6) CD34/kg) remaining for amyeloablative transplant. Thus, new
approaches are needed.We therefore initiated a pilot clinical trial to
enable the successful reconstitution of blood counts in patients with
RRMM so they could proceed onto new clinical trials and test the
synergy of bortezomib and melphalan clinically in non-myeloabla-
tive doses (stem cell boost). We have treated 9 patients with
RRMM who have failed novel agents (including bortezomib) and
chemotherapy (dexamethasone, cytoxan, etoposide, cisplatin, and
doxil) and who had only limited duration of response previously
with high dose melphalan. All patients were cytopenic (ANC \
1000 and/or platelets\ 50,000/ mcl) and thus not eligible for new
clinical trials. The melphalan was given at 30–50 mg/m2 on days 1
and 4, depending on the age and performance status of the patient.
Bortezomib at 1.3 mg/m2 was given on the same days after the mel-
phalan. The patients then received 1.5 to 2.2 10(6) CD34 cells/kg.
(depending upon the amount of remaining stem cells). We have seen
responses (.25%) in all 9, with.PR in 8 and VGPR in 1. More im-
portantly, all patients successfully engraftedWBC.2000 and plate-
lets.50,000/mcl. Duration of response was 2 months or greater and
all patients were able to proceed on to new clinical trials. All patients
were given treatment as outpatient and average duration of hospital-ization was 3 days (range 0 to 6) during cytopenia. Thus, the clinical
synergy between bortezomib and melphalan can lead to an effective
salvage strategy even for cytopenic patients with relapsed and refrac-
tory multiple myeloma. This non-myeloablative approach could
serve as a platform for proceeding on to new clinical trials for those
advanced patients without adequate numbers of stem cells for a -
myeloablative transplant.PEDIATRIC DISORDERS
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OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTSWITH PRIMARY AND SECONDARYMYELO-
DYSPLASTIC SYNDROMES
Parikh, S.H.1, Mendizabal, A.2, Betz-Stablein, B.2, Martin, P.L.1,
Szabolcs, P.1, Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2Emmes Corporation,
Rockville, MD
Myelodysplastic syndromes (MDS) respond poorly to chemother-
apy alone. Between 1995 and 2006, 23 pediatric patients with MDS
were transplanted with unrelated donor umbilical cord blood
(UCB) at our center. The median age was 11.09 yrs (range 1.11–
19.73); 20% of patients were male; median time from diagnosis to
transplant was 6.57 mo (range 2.00–61.37). Patients were followed
for amedianof 5.3 yrs (range1.64–12.36) post-transplant.MDSstage
wasRA/RC12pts,RAEB8pts andRAEB-T3pts; 78.3%pts hadpri-
maryMDS.Monosomy7waspresent in 17(74%)of patients. Patients
with frank AML were excluded. Preparative regimen was TBI based
in 18 (78%) pts and melphalan was used in 14 (61%) of patients.
GVHD prophylaxis consisted of CSA/steroids (19 pts) and CSA/
MMF (4 pts). Grafts were HLA matched at Class I (A and B) at low
resolution and Class II (DRB1) at the allelic level resulting in
16(70%) 4/6 and 7(30%) 5/6 matched transplants. The grafts con-
tained amedian of 4.04 107 (range 1.68–12.58) total nucleated cells
(TNC)/kg pre-cryopreservation; 3.58  107 (range 1.01–12.00)
TNC/kg and1.72 105 (range 0.17–28.46)CD341 cells/kgwere in-
fused. Cumulative incidence of neutrophil engraftment (ANC.500/
mL) at days 42 & 100 was 73.9% (95%CI 55.1%–92.7%) and 91.3%
(95%CI71.3%–100%), and that of platelet engraftment (50K) at 180
days was 69.6% (49.8%–89.4%). Three pts had graft failure while 3
pts (13%) engrafted slowly (after Day 42), perhaps related to some
underlying marrow dysfunction caused by MDS. Three patients de-
veloped acuteGvHDgrades II-IVwith a cumulative incidence at 100
Days of 13% (95% CI 0.0%–27.1.0%). Four patients relapsed with
a CI of relapse at 3 yrs of 13.0% (95%CI 0.0%–27.1%). Cumulative
incidence of non-relapse mortality at 1 yr was 27% (95% CI 8.0%–
46.0%). Ten pts died: 3 graft failure, 4 relapse, 2 infections (1 adeno-
virus, 1 toxoplasmosis), and 1 EBVLPD.Overall survival probability
at 1 and3 yearswere 69.6%(95%CI46.6%–84.2%) and59.2% (95%
CI 35.9%–76.5%) respectively. Event-free survival (EFS) probabili-
ties at 1 and 3 years were 69.6% (95% CI 46.6%–84.2%) and 60.9%
(38.3%–77.4%) respectively. Factors associated with better EFS
were age # 10 yrs (p 5 0.05) and weight # 38 kg (p 5 0.03). These
results, especially in younger pts with Monosomy 7 and MDS, are
equivalent to published matched allogeneic bone marrow data.
UCB should be actively considered for pediatric MDS pts lacking
matched related or unrelated adult donors.197
A PHASE I/II STUDY OF CYCLOPHOSPHAMIDE AND TOPOTECAN IN PA-
TIENTS WITH HIGH-RISK MALIGNANCIES UNDERGOING AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE ST. JUDE LONG-
TERM FOLLOW-UP
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